Title: Influenza Vaccination of Healthcare Personnel HCP
1Influenza Vaccination of Health-care Personnel
(HCP)
- National Influenza Vaccination Week (NIVW)
- Andrew Kroger
2Which HCP Need Vaccination?
- Includes physicians, nurses, nursing assistants,
therapists, technicians, EMTs, dental,
pharmacists, laboratory personnel, autopsy,
students, trainees, contract staff, persons
potentially exposed to infectious agents that can
be transmitted to and from HCP. - Settings include hospitals, nursing homes,
skilled nursing facilities, physicians offices,
urgent care centers, outpatient clinics, home
healthcare, and emergency medical services
3Overview
- Nosocomial influenza epidemiology
- Health-care personnel influenza vaccine coverage
- Strategies to improve health-care personnel
vaccination
4Nosocomial Influenza
- Transmission that occurs in a health-care setting
- Can result from under-vaccination of health-care
personnel
5Nosocomial Influenza
- In a tertiary care facility 1987-2000
- Staff influenza vaccination coverage
- 4 gtgtgt 67
- Staff influenza disease
- 42 gtgtgt 9
- Nosocomial Disease
- 32 gtgtgt 0 cases
- Salgado CD, Infection Control Hospital
Epidemiology, 2004
6Influenza in Nursing Homes
- Influenza Attack Rates
- 25-60
- Case-fatality 10-20
7Influenza in Nursing Homes
- Randomized control study
- Staff vaccination led to an 43 decrease in ILI
- 44 decrease in mortality
- Potter J, et. Al. J Infect Dis. 1997
8Nosocomial Influenza
- Health-care personnel can be infected by their
patients - Prospective study vaccinated health-care
personnel - 30 fewer ILI
- 63 fewer illnesses with fever and cough
9- Prepared by Michele L. Pearson, MD1 Carolyn B.
Bridges, MD2 Scott A. Harper, MD3
10Health-care Personnel Vaccination Coverage
- In the 2006 National Health Interview Survey,
only 42 of HCP reported receiving influenza
vaccine in the previous 12 months
11Health-care Personnel Vaccination Strategies
- Education/campaigns
- Vaccination of role models
- Improving vaccine access
- Measurement and feedback
- Legislation and regulation
12Influenza Vaccination Barriers Amenable to
Education
- Fear of side effects
- Perceived ineffectiveness
- Perception of low risk
- Fear of needles
13Inactivated Influenza Vaccine (TIV) Adverse
Reactions
- Local reactions 15-20
- Fever, malaise not common
- Allergic reactions rare
14Live Attenuated Influenza Vaccine (LAIV) Adverse
Reactions
- Children
- Increased risk of asthma or reactive airways
disease in children 12-59 months of age - Adults
- Increased rate of cough, runny nose, nasal
congestion, sore throat, and chills reported
among vaccine recipients
15- TIV contains only noninfectious fragments of
influenza virus - LAIV cannot replicate in the lower respiratory
track - Neither vaccine can cause influenza disease
16TIV Efficacy
- 70 - 90 effective among healthy persons younger
than 65 years of age - 30 - 40 effective among elderly persons
- 50 - 60 effective in preventing hospitalization
- 80 effective in preventing death
17LAIV Efficacy
- 85 effective following experimental challenge
- Effective against complications of influenza
- Children otitis media 27 effective
- Adults febrile respiratory illness 27
18Influenza Disease Risk Perception
- HCP influenza infection rates
- Sero-surveys 23
- Placebo recipients 13
- Cross-sectional surveys (ILI) 37
- Wilde JA, et. Al. JAMA 1999
- Lester RT, et. Al. Infect Control Hosp Epidemiol
2003
19(No Transcript)
20Improving Influenza Vaccine Access
- Clinics
- Conferences
- Mobile Carts
21Measurement and Feedback
- Posting vaccination rates in selected areas of
the hospital - HICPAC recommends influenza vaccination rates as
a quality-measure
22Legislation and Regulation
- Official health agencies should take necessary
steps, including, when appropriate, developing
and enforcing child care and school vaccination
requirements, to ensure that students at all
grade levels (including college) and children in
day care centers are protected against
vaccine-preventable diseases
- Centers for Disease Control and Prevention.
General Recommendations on Immunization. MMWR
200655(No. RR-15)38.